Vivos (RDGL) Cash from Investing Activities (2010 - 2017)

Vivos' (RDGL) quarterly Cash from Investing Activities came in at $2800.0 in Q1 2017, up 280100.0% quarter-over-quarter from -$1.0 in Q4 2013.

Vivos (RDGL) Cash from Investing Activities (2010 - 2017) Analysis & Trends

Vivos has disclosed Cash from Investing Activities across 5 years of filings, most recently posting $2800.0 for Q1 2017.

  • Cash from Investing Activities for Q1 2017 came in at $2800.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2017 was $2800.0 (changed N/A YoY), and the FY2025 annual result was -$103185.0, changed N/A from the prior year.
  • Cash from Investing Activities came in at $2800.0 for Q1 2017 at Vivos, up from -$1.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $16789.0 in Q2 2013 to a low of -$24504.0 in Q1 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn -20.32 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn -185.00 Mn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn -816.00 Mn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn -591.00 Mn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn -92.80 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -475.32 Mn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn -298.50 Mn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn -2.50 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn -217.20 Mn
10 Vivos - - -3,105.00 -

Historic Data

Download Data
DateValue
Mar 31, 2017 2,800.00
Mar 31, 2017 2,800.00
Dec 31, 2013 -1.00
Dec 31, 2013 -1.00
Jun 30, 2013 16,789.00
Jun 30, 2013 16,789.00
Mar 31, 2013 -24,504.00
Mar 31, 2013 -24,504.00
Dec 31, 2012 22,016.00
Dec 31, 2012 22,016.00
Sep 30, 2012 -35,871.00
Sep 30, 2012 -35,871.00
Jun 30, 2012 -29,178.00
Jun 30, 2012 -29,178.00
Mar 31, 2012 -49,129.00
Mar 31, 2012 -49,129.00
Dec 31, 2011 -20,327.00
Dec 31, 2011 -20,327.00
Sep 30, 2011 -9,159.00
Sep 30, 2011 -9,159.00